Health Current

Arizona Health-e Connection Is Now Health Current Powering the future of healthcare with more complete information. Health Current is the health information exchange (HIE) that helps partners transform care by bringing together communities and information across Arizona. More complete information is more meaningful and leads to better care and better outcomes. It makes healthcare transformation possible. That’s why we’ve worked for more than ten years to become Arizona’s primary resource for information technology and exchange, integrating information with the delivery of care to improve the health and wellbeing of individuals and communities. As we’ve grown, our core goal has remained the same: help providers use information technology to improve people’s lives.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

news image

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More

INDUSTRY OUTLOOK

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

news image

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

news image

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

news image

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More
news image

WITH AN EYE ON THE CLINIC, ATLAS-BACKED KYMERA SECURES $102 MILLION

BioSpace | March 12, 2020

Cambridge, Mass.-based Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology. Kymera's lead program targets IRAK4, a protein that is known to play a significant role in inflammation that is mediated by toll-like and IL-1 receptors. Kymera aims to advance its IRAK4 degrader program in a variety of autoinflammatory and autoimmune diseases, as well as in precision-medicine ta...

Read More
news image

INDUSTRY OUTLOOK

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More
news image

INDUSTRIAL IMPACT

LEGEND BIOTECH ANNOUNCES EXTENSION OF PDUFA DATE FOR CILTA-CEL

Cilta-cel | November 01, 2021

Legend Biotech Corporation (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act (PDUFA) target date for ciltacabtagene autoleucel (cilta-cel) to February 28, 2022. Cilta-cel is a BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy being investigated for the treatment of adults with relapsed and/or refractory multiple myelo...

Read More
news image

TRANSPOSABLE ELEMENTS ROLE IN GENETIC EXPRESSION COULD IMPROVE STUDY OF NEURODEGENERATIVE DISEASE

GEN | April 15, 2020

Researchers in Michigan published a study “Transposable elements contribute to cell and species-specific chromatin looping and gene regulation in mammalian genomes” in Nature Communications that shows that transposable elements play an important role in regulating genetic expression with implications to advance the understanding of genetic evolution, with potential applications in neurodegenerative diseases. Transposable elements move around the cell, and, unlike previously thought, ...

Read More